Core Viewpoint - The article discusses the development and potential of in vivo CAR-T cell therapy, particularly focusing on Capstan Therapeutics and its innovative approach to treating cancer and autoimmune diseases through a new mRNA delivery system [2][3][19]. Group 1: In Vivo CAR-T Technology - In vivo CAR-T technology allows for the generation of CAR-T cells directly within the body through the injection of lipid nanoparticles (LNP) delivering mRNA, addressing challenges such as complexity, time, and cost associated with traditional CAR-T therapies [2][3]. - Capstan Therapeutics, founded by leading researchers in the field, has secured $340 million in funding to advance this technology for various diseases [2][3]. Group 2: Clinical Trials and Research Findings - Capstan's CAR-T therapy CPTX2309 has commenced Phase 1 clinical trials for treating B cell-mediated autoimmune diseases [3]. - Preclinical studies demonstrated that the proprietary targeted lipid nanoparticles (tLNP) effectively delivered CAR mRNA to CD8+ T cells, showing promising therapeutic prospects and safety in animal models [3][4]. Group 3: Market Potential and Patient Demographics - The patient population for autoimmune diseases is significantly larger than that for B cell malignancies, with approximately 20 million individuals in the U.S. and 10% of the global population affected [6]. - There is a pressing need for scalable, off-the-shelf therapies that do not require chemotherapy preconditioning and can be administered in non-specialized medical centers [6]. Group 4: Mechanism and Efficacy - The research team developed a novel ionizable lipid L828 and optimized the LNP formulation to enhance targeting and accumulation in the liver while minimizing off-target effects [7]. - The CD8-L829-tLNP demonstrated a preference for modifying CD8+ T cells over CD4+ T cells, leading to effective targeting and destruction of B cells in both humanized mouse models and non-human primate models [9][10]. Group 5: Safety and Tolerability - In non-human primate studies, the treatment showed good tolerability, although some adverse effects were noted, such as a known side effect of CAR-T therapy [16]. - The study indicated that the treatment led to a temporary depletion of B cells, suggesting a reset of the immune system, which is crucial for long-term therapeutic benefits [16][19].

SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key corporate highlights. "CARVYKTI, underpinned by its continued strong commercial performance, continues to set the standard for CAR-T therapies in multiple myeloma," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We believe our achievements from this past quarter, including c ...

Company Overview - Legend Biotech Corporation is a global leader in cell therapy with over 2,500 employees, making it the largest standalone cell therapy company [3] - The company is pioneering treatments that aim to revolutionize cancer care, particularly through its CAR-T cell therapy [3] - CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, is developed and marketed in collaboration with Johnson & Johnson [3] Upcoming Events - Legend Biotech will host a conference call for investors on May 13, 2025, at 8:00 am ET to review first-quarter 2025 results [1] - Senior leaders will provide an overview of the company's performance during the call [1] - A replay of the webcast and earnings news release will be available approximately two hours after the call concludes [2]

Core Viewpoint - Mustang Bio, Inc. has exited its lease for a manufacturing facility in Worcester, Massachusetts, and divested certain fixed assets to AbbVie for $1.0 million, while relocating its corporate headquarters to Waltham, Massachusetts [1][2]. Group 1: Financial Implications - The termination of the lease is expected to result in approximately $2.0 million in cash expense savings over the next 24 months [2]. - The divestment of fixed assets to AbbVie Bioresearch Center Inc. was completed for a total of $1.0 million [1]. Group 2: Strategic Focus - The company remains committed to advancing its existing portfolio and plans to initiate a novel clinical trial with MB-109, targeting recurrent glioblastoma and high-grade astrocytomas in the second half of 2025 [3]. - MB-109 is a combination therapy that includes MB-101 (IL13Rα2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), aimed at enhancing the efficacy of CAR-T cell therapy by modifying the tumor microenvironment [4]. Group 3: Company Overview - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, partnering with leading medical institutions to advance CAR-T therapies [5].